TABLE 3.

Covariate-adjusted cumulative incidence of symptom relief when drop out due to worsening of symptoms was treated as a competing risk.

Covariates	Hazard ratio (95%CI)	p-value
Fever
Treatment: Kampo medicine group vs. Control group	1.76 (1.03–3.01)	0.0385
Age: <45 vs. ≥45, years	2.56 (1.37–4.78)	0.0031
Duration of disease: ≤7 vs. >7, days	0.82 (0.39–1.72)	0.6033
Severity: moderate stage Ⅰ vs. mild	0.95 (0.55–1.65)	0.8651
Vaccination: Yes vs. No	1.77 (0.82–3.82)	0.1434
Baseline of fever, °C	0.57 (0.37–0.90)	0.0148
Cough
Treatment: Kampo medicine group vs. Control group	1.07 (0.76–1.51)	0.7121
Age: <45 vs. ≥45, years	2.30 (1.49–3.56)	0.0002
Duration of disease: ≤7 vs. >7, days	1.21 (0.79–1.87)	0.3779
Severity: moderate stage Ⅰ vs. mild	1.28 (0.86–1.89)	0.2238
Vaccination: Yes vs. No	3.26 (2.29–4.66)	<0.0001
Baseline of cough	1.25 (1.12–1.39)	<0.0001
Sputum
Treatment: Kampo medicine group vs. Control group	1.02 (0.66–1.58)	0.9306
Age: <45 vs. ≥45, year	2.57 (1.52–4.35)	0.0004
Duration of disease: ≤7 vs. >7, days	0.95 (0.55–1.66)	0.8663
Severity: moderate stage Ⅰ vs. mild	1.47 (0.93–2.35)	0.1025
Vaccination: Yes vs. No	3.17 (2.14–4.69)	<0.0001
Baseline of sputum	1.26 (1.06–1.49)	0.0079
Fatigue
Treatment: Kampo medicine group vs. Control group	1.24 (0.83–1.87)	0.2919
Age: <45 vs. ≥45, year	1.52 (0.94–2.47)	0.0905
Duration of disease: ≤7 vs. >7, days	0.89 (0.58–1.37)	0.6092
Severity: moderate stage Ⅰ vs. mild	0.86 (0.55–1.34)	0.4955
Vaccination: Yes vs. No	0.80 (0.19–3.29)	0.7530
Baseline of fatigue	1.03 (0.91–1.16)	0.6547
Shortness of breath
Treatment: Kampo medicine group vs. Control group	1.12 (0.62–2.02)	0.7127
Age: <45 vs. ≥45, year	2.84 (1.17–6.89)	0.0208
Duration of disease: ≤7 vs. >7, days	0.83 (0.45–1.51)	0.5357
Severity: moderate stage Ⅰ vs. mild	1.35 (0.68–2.65)	0.3927
Vaccination: Yes vs. No	3.92 (1.21–12.72)	0.0230
Baseline of shortness of breath	1.04 (0.76–1.44)	0.7912